{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:47:40Z","timestamp":1789001260696,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013061","name":"Jilin Provincial Scientific and Technological Development Program","doi-asserted-by":"publisher","award":["20220508087RC"],"award-info":[{"award-number":["20220508087RC"]}],"id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.neuroscience.2025.12.064","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:07:16Z","timestamp":1767859636000},"page":"36-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The efficacy of combination therapy versus monotherapy in patients with glioblastoma with abnormal epidermal growth factor receptor (EGFR) genes, a systematic review and network meta-analysis"],"prefix":"10.1016","volume":"596","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-5314","authenticated-orcid":false,"given":"Liding","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejiao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokai","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luhao","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songbai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.neuroscience.2025.12.064_b0005","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3892\/ol.2025.14989","article-title":"Key genes altered in glioblastoma based on bioinformatics (Review)","volume":"29","author":"Al Ghafari","year":"2025","journal-title":"Oncol. Lett."},{"issue":"22","key":"10.1016\/j.neuroscience.2025.12.064_b0010","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.3390\/cancers13225799","article-title":"Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?","volume":"13","author":"Aldaz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.neuroscience.2025.12.064_b0015","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.neuroscience.2022.03.030","article-title":"Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme","volume":"491","author":"Aldoghachi","year":"2022","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/j.neuroscience.2025.12.064_b0020","article-title":"Anti-angiogenic therapy for high-grade glioma","volume":"11","author":"Ameratunga","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.neuroscience.2025.12.064_b0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/pharmaceutics15010059","article-title":"Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery","volume":"15","author":"Brar","year":"2022","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.neuroscience.2025.12.064_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2025.12.064_b0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jclinepi.2016.11.015","article-title":"Additional considerations are required when preparing a protocol for a systematic review with multiple interventions","volume":"83","author":"Chaimani","year":"2017","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.neuroscience.2025.12.064_b0040","article-title":"Anti-PD-1 and anti-PD-L1 antibodies for glioma","volume":"1","author":"de Melo","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"issue":"14","key":"10.1016\/j.neuroscience.2025.12.064_b0045","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.7150\/jca.30123","article-title":"Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial","volume":"10","author":"Du","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.neuroscience.2025.12.064_b0050","article-title":"Metabolic Rewiring in Glioblastoma Cancer: EGFR","volume":"12","author":"El Khayari","year":"2022","journal-title":"IDH and Beyond. Frontiers in oncology"},{"issue":"1","key":"10.1016\/j.neuroscience.2025.12.064_b0055","article-title":"Transcriptomic analysis of EGFR co-expression and activation in glioblastoma reveals associations with its ligands","volume":"7","author":"Ghisai","year":"2024","journal-title":"Neuro-Oncol. Adv."},{"key":"10.1016\/j.neuroscience.2025.12.064_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocn.2025.111138","article-title":"The safety and efficacy of tyrosine kinase inhibitors against EGFR in patients with glioma; A systematic review, meta-analysis, and sub-group analysis on glioblastoma","volume":"135","author":"Habibi","year":"2025","journal-title":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia"},{"issue":"15","key":"10.1016\/j.neuroscience.2025.12.064_b0065","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-24-0426","article-title":"Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models","volume":"30","author":"Jain","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.neuroscience.2025.12.064_b0070","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3390\/ijms21020547","article-title":"Open Data for Differential Network Analysis in Glioma","volume":"21","author":"Jean-Quartier","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.neuroscience.2025.12.064_b0075","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1001\/jama.2016.7602","article-title":"Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis","volume":"315","author":"Khera","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.neuroscience.2025.12.064_b0080","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.3390\/ijms25053040","article-title":"Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers","volume":"25","author":"Lan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2025.12.064_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.662302","article-title":"A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis","volume":"11","author":"Lara-Velazquez","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.neuroscience.2025.12.064_b0090","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/neuonc\/noac173","article-title":"Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial","volume":"25","author":"Lassman","year":"2023","journal-title":"Neuro Oncol."},{"issue":"16","key":"10.1016\/j.neuroscience.2025.12.064_b0095","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-14-3220","article-title":"A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.neuroscience.2025.12.064_b0100","article-title":"Anti-epidermal growth factor receptor therapy for glioblastoma in adults","volume":"5","author":"Lee","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"issue":"22","key":"10.1016\/j.neuroscience.2025.12.064_b0105","doi-asserted-by":"crossref","first-page":"33440","DOI":"10.18632\/oncotarget.7961","article-title":"PI3K\/Akt\/mTOR signaling pathway and targeted therapy for glioblastoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.neuroscience.2025.12.064_b0110","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/vaccines11091460","article-title":"Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma","volume":"11","author":"Li","year":"2023","journal-title":"Vaccines"},{"issue":"8","key":"10.1016\/j.neuroscience.2025.12.064_b0115","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neuroscience.2025.12.064_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctcp.2020.101260","article-title":"Comparative effectiveness of breathing exercises in patients with chronic obstructive pulmonary disease","volume":"41","author":"Marotta","year":"2020","journal-title":"Complement. Ther. Clin. Pract."},{"issue":"1","key":"10.1016\/j.neuroscience.2025.12.064_b0125","article-title":"Treatment options for progression or recurrence of glioblastoma: a network meta-analysis","volume":"5","author":"McBain","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.neuroscience.2025.12.064_b0130","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/WCO.0000000000000491","article-title":"The promises of immunotherapy in gliomas","volume":"30","author":"Mildenberger","year":"2017","journal-title":"Curr. Opin. Neurol."},{"issue":"2","key":"10.1016\/j.neuroscience.2025.12.064_b0135","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-024-04865-2","article-title":"Angiogenesis inhibitors effects on overall survival and progression-free survival in newly diagnosed primary glioblastoma multiforme: a meta-analysis of twelve randomized clinical trials","volume":"171","author":"Motamed-Sanaye","year":"2025","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.neuroscience.2025.12.064_b0140","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/OTT.S215997","article-title":"Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations","volume":"15","author":"Niedba\u0142a","year":"2022","journal-title":"OncoTargets and therapy"},{"issue":"5","key":"10.1016\/j.neuroscience.2025.12.064_b0145","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3390\/ijms25052529","article-title":"Glioblastoma Therapy: Past, Present and Future","volume":"25","author":"Obrador","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2025.12.064_b0150","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.574012","article-title":"A Review of Newly Diagnosed Glioblastoma","volume":"10","author":"Oronsky","year":"2021","journal-title":"Front. Oncol."},{"issue":"Suppl 5","key":"10.1016\/j.neuroscience.2025.12.064_b0155","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol."},{"issue":"11","key":"10.1016\/j.neuroscience.2025.12.064_b0160","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.3390\/cancers13112773","article-title":"Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)","volume":"13","author":"Padovan","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.neuroscience.2025.12.064_b0165","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s12672-025-02567-3","article-title":"Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance","volume":"16","author":"Pu","year":"2025","journal-title":"Discov Onc"},{"issue":"3","key":"10.1016\/j.neuroscience.2025.12.064_b0170","first-page":"430","article-title":"Phase I\/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma","volume":"17","author":"Reardon","year":"2015","journal-title":"Neuro Oncol."},{"issue":"7","key":"10.1016\/j.neuroscience.2025.12.064_b0175","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-18-1140","article-title":"Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial","volume":"26","author":"Reardon","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"25","key":"10.1016\/j.neuroscience.2025.12.064_b0180","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026432","article-title":"Extent of resection and survival in patients with glioblastoma multiforme: Systematic review and meta-analysis","volume":"100","author":"Revilla-Pacheco","year":"2021","journal-title":"Medicine"},{"issue":"13","key":"10.1016\/j.neuroscience.2025.12.064_b0185","doi-asserted-by":"crossref","first-page":"11110","DOI":"10.3390\/ijms241311110","article-title":"An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma","volume":"24","author":"Rodriguez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuroscience.2025.12.064_b0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern. Emerg. Med."},{"issue":"2","key":"10.1016\/j.neuroscience.2025.12.064_b0195","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"31","key":"10.1016\/j.neuroscience.2025.12.064_b0200","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","article-title":"Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma","volume":"28","author":"Sampson","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.neuroscience.2025.12.064_b0205","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-021-03877-6","article-title":"Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial","volume":"155","author":"Saran","year":"2021","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.neuroscience.2025.12.064_b0210","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ (Clinical research ed.)"},{"issue":"1","key":"10.1016\/j.neuroscience.2025.12.064_b0215","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/oncolo\/oyac202","article-title":"Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study","volume":"28","author":"She","year":"2023","journal-title":"Oncologist"},{"issue":"23","key":"10.1016\/j.neuroscience.2025.12.064_b0220","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.neuroscience.2025.12.064_b0225","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3389\/fendo.2018.00318","article-title":"Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions","volume":"9","author":"Syro","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"10","key":"10.1016\/j.neuroscience.2025.12.064_b0230","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","article-title":"Epidemiologic and molecular prognostic review of glioblastoma","volume":"23","author":"Thakkar","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"2","key":"10.1016\/j.neuroscience.2025.12.064_b0235","article-title":"Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochimica et biophysica acta","volume":"1876","author":"Tomar","year":"2021","journal-title":"Reviews on cancer"},{"issue":"8","key":"10.1016\/j.neuroscience.2025.12.064_b0240","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2008.17.5984","article-title":"Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034","volume":"27","author":"van den Bent","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.neuroscience.2025.12.064_b0245","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/neuonc\/noz222","article-title":"INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma","volume":"22","author":"Van Den Bent","year":"2020","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1016\/j.neuroscience.2025.12.064_b0250","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/biomet\/asz002","article-title":"Multivariate output analysis for Markov chain Monte Carlo","volume":"106","author":"Vats","year":"2019","journal-title":"Biometrika"},{"issue":"5","key":"10.1016\/j.neuroscience.2025.12.064_b0255","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3390\/cancers17050744","article-title":"Clinical Impact of a Next-Generation Sequencing Approach for Glioblastoma Patients","volume":"17","author":"Vivancos S\u00e1nchez","year":"2025","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.neuroscience.2025.12.064_b0260","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.neuroscience.2025.12.064_b0265","doi-asserted-by":"crossref","unstructured":"Westphal, M. et al., 2015. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. European journal of cancer (Oxford, England : 1990), 51(4), 522\u2013532. https:\/\/doi.org\/10.1016\/j.ejca.2014.12.019.","DOI":"10.1016\/j.ejca.2014.12.019"},{"issue":"1\u20132","key":"10.1016\/j.neuroscience.2025.12.064_b0270","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0165-5728(93)90246-U","article-title":"Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas","volume":"46","author":"Wikstrand","year":"1993","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuroscience.2025.12.064_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105780","article-title":"Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance","volume":"171","author":"Wu","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.neuroscience.2025.12.064_b0280","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11060-024-04932-8","article-title":"Nimotuzumab and bevacizumab combined with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma multiforme: a retrospective single-arm study","volume":"172","author":"Wu","year":"2025","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.neuroscience.2025.12.064_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanwpc.2023.100715","article-title":"National Brain Tumour Registry of China (NBTRC) statistical report of primary brain tumours diagnosed in China in years 2019-2020","volume":"34","author":"Xiao","year":"2023","journal-title":"The Lancet regional health. Western Pacific"},{"key":"10.1016\/j.neuroscience.2025.12.064_b0290","first-page":"819","article-title":"Profile of nimotuzumab in the treatment of high-grade glioma","volume":"8","author":"Yang","year":"2015","journal-title":"OncoTargets and therapy"},{"issue":"8","key":"10.1016\/j.neuroscience.2025.12.064_b0295","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.3390\/ijms26083539","article-title":"The Prognostic Significance of Epidermal Growth Factor Receptor Amplification and Epidermal Growth Factor Receptor Variant III Mutation in Glioblastoma: A Systematic Review and Meta-Analysis with Implications for Targeted Therapy","volume":"26","author":"Zhu","year":"2025","journal-title":"Int. J. Mol. Sci."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030645222501231X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030645222501231X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:39:47Z","timestamp":1775900387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030645222501231X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":59,"alternative-id":["S030645222501231X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2025.12.064","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of combination therapy versus monotherapy in patients with glioblastoma with abnormal epidermal growth factor receptor (EGFR) genes, a systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2025.12.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}